[THE NEW YORK TIMES] Bausch & Lomb, the eye care company, agreed on Monday to sell itself to Valeant Pharmaceuticals International of Canada for about $8.7 billion, sidestepping the lengthier process of an initial public offering. Under the terms of the deal, Valeant will pay $4.5 billion to the investor group that owns Bausch & Lomb, led […]